TransMedics Group Inc. (TMDX)
Betting Big On TransMedics (Q2 2024 Update)
TransMedics Group, Inc. reported 117.9% YoY revenue growth in Q2 2024 and raised full-year guidance significantly, showcasing strong financial performance. Acquisition of Summit Aviation and building the largest transplant logistics network in the US enhances its competitive moat. Conservative guidance, potential for continued revenue and margin expansion, and robust management led by a visionary CEO position, position TransMedics Group for sustained growth.
Can TransMedics (TMDX) Run Higher on Rising Earnings Estimates?
TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
TransMedics Group: Providing Long-Term Detailed Forecast And Upgrading To Buy
TransMedics Group had a remarkable second quarter, beating revenue estimates and raising guidance. The company's National Organ Care Systems Program is driving growth, with liver revenues up 2.4x and heart revenues doubling year over year. Long-term valuation model predicts significant EPS growth, with potential for the stock to reach $265 a share by 2026, representing 75% upside.
Compared to Estimates, TransMedics (TMDX) Q2 Earnings: A Look at Key Metrics
The headline numbers for TransMedics (TMDX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Why TransMedics Group Stock Is Soaring Today
TransMedics Group reported significant top- and bottom-line improvement in Q2. The company raised its full-year revenue guidance.
TransMedics Group Raises Full-Year Guidance
Revenue of $114.3 million, a 118% increase year over year. Full-year revenue guidance increased to $425 million to $445 million.
TransMedics Group, Inc. (TMDX) Q2 2024 Earnings Call Transcript
TransMedics Group, Inc. (TMDX) Q2 2024 Earnings Call Transcript
TransMedics (TMDX) Q2 Earnings and Revenues Top Estimates
TransMedics (TMDX) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to loss of $0.03 per share a year ago.
Wall Street's Insights Into Key Metrics Ahead of TransMedics (TMDX) Q2 Earnings
Get a deeper insight into the potential performance of TransMedics (TMDX) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
TransMedics (TMDX) Moves to Buy: Rationale Behind the Upgrade
TransMedics (TMDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Vertex Pharmaceuticals could have multiple new blockbusters on the way. Viking Therapeutics is targeting two massive markets -- obesity and NASH.
TransMedics (TMDX) Just Reclaimed the 20-Day Moving Average
TransMedics (TMDX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TMDX crossed above the 20-day moving average, suggesting a short-term bullish trend.
